



**Supplemental information**

**Extracellular matrix protein composition dynamically changes during murine forelimb development**

**Kathryn R. Jacobson, Aya M. Saleh, Sarah N. Lipp, Chengzhe Tian, Audrey R. Watson, Callan M. Luetkemeyer, Alexander R. Ocken, Sabrina L. Spencer, Tamara L. Kinzer-Ursem, and Sarah Calve**




**Figure S1. Proteomic analysis of fractionated murine embryonic tissues confirmed enrichment of matrisome in the insoluble (IN) fraction. Related to Figures 1 and 2. (A)** Experimental workflow combining tissue fractionation with LC-MS/MS to investigate the ECM protein composition of embryonic tissues. **(B)** The distribution of protein IDs and raw protein intensities in the homogenate and fractions of E12.5 murine embryos (average,  $n=2$  biological replicates), revealed a significant increase in percent matrisome in the IN pellet, compared to the homogenate and other fractions ( $p<0.001$ , one-way ANOVA). **(C)** The top 5 significant “Cellular Component” and “Biological Process” terms generated by GO analysis of the 50 most abundant proteins within each CNM (combined C, N and M), CS and IN fraction of E14.5 whole embryos and forelimbs indicated successful enrichment of ECM-related GO terms in the IN fraction. **(D)** The majority of ECM proteins were identified in both the CS and IN fractions of E11.5-E14.5 forelimbs. **(E)** The average amount of total protein (black) and matrisome (grey) in one forelimb (average and standard deviation of  $n=3$ ). **(F)** Row z-scores were calculated for the normalized LFQ intensities in the IN fraction (left) and combined intensities (right). By combining CS and IN intensities, the number of ECM protein identifications increased, but overall matrisome dynamics did not change. For heat map analysis, white boxes signify proteins not identified in  $n\geq 2$  biological replicates. **(G)** The percentage of combined LFQ intensity from the IN fraction was protein and timepoint specific. Percentages were plotted as the average across biological replicates ( $n=3$ ). Grey boxes denote protein intensities identified exclusively in the CS fraction.




**Figure S2. ECM expression by different cell types of the developing forelimb as identified via scRNA-sequencing. Related to Figure 2.** Analysis of published scRNA-seq data<sup>3</sup> provided insight into the cell types that had the potential to

contribute to the synthesis of different ECM. **(A, B)** C1 Fluidigm (A) and 10X Genomics (B) scRNA-seq data sets were analyzed for ECM expression profiles and presented as dot plots to identify enriched genes in each cell type. Cell types were clustered and classified as described in <sup>3</sup>. Color indicates the  $\log_2(\text{average expression} + 1)$  and circle size represents the percentage of cells expressing that transcript. **(C, D)** Distribution of cell types identified as a function of age by C1 Fluidigm (C) or 10X Genomics (D). **(E)** Gene expression levels during limb development (E11.5-E14.5) for the nascent ECM identified 6-hpi between E13.5-E14.5 (**Figure 2D**), based on bulk RNA-seq data generated by <sup>3</sup>. The x-axis represents forelimb development, and the y-axis represents the average  $\log_2$  fold-change of gene expression compared to the timepoint of injection, E13.5 ( $n \geq 2$ ). Dashed horizontal lines depict fold-change of  $\pm 2$ .




**Figure S3. Spatiotemporal distribution of collagens, type I and V, during forelimb development show differential patterning of proteins. Related to Figure 4. (A-DD)** Cryosections from E11.5 – E14.5, P3 and adult were stained with antibodies against: **(A-F, A'-D')** type I collagen (COL I; green); **(G-L, G'-J')** type V collagen (COL V; red); **(M-R, M'-P')** myosin heavy chain, a marker for differentiated skeletal muscle (MY32; blue); **(S-X, S'-V')** merge (green, red, blue); and **(Y-DD, Y'-BB')** merge with DAPI (grey). **(EE-PP)** Secondary antibody only negative controls: **(EE-JJ)** merge; and **(KK-PP)** merge with DAPI. Insets (indicated with ') are a 3× enlargement of the region containing the nascent elbow (\*) for E11.5-E14.5. Scale bars=200 μm.



**Figure S4. Spatiotemporal distribution of tenascin-C, fibrillin-2 and nidogen-2 during forelimb development show differential patterning of proteins. Related to Figure 4. (A-DD)** Cryosections from E11.5 – E14.5, P3 and adult were stained with antibodies against: **(A-F, A'-D')** tenascin-C (TNC; green); **(G-L, G'-J')** fibrillin-2 (FBN2; red); **(M-R, M'-P')** nidogen-2 (NID2; blue); **(S-X, S'-V')** merge (green, red, blue); and **(Y-DD, Y'-BB')** merge with DAPI (grey). **(EE-PP)** Secondary antibody only negative controls: **(EE-JJ)** merge; and **(KK-PP)** merge with DAPI. Insets (indicated with ') **(R')** NID2 and **(X')** TNC/FBN2/NID2 merge channels showed punctate staining (arrow) of NID2 in the adult. White box in **(R)** and **(X)** highlighted the inset location. Other insets are a 3× enlargement of the region containing the nascent elbow (\*) for E11.5–E14.5. Scale bars=200 μm.





**Figure S5. Spatiotemporal distribution of elastin microfibril interfacier 1 (EMILIN1) and perlecan (HSPG2) during forelimb development show differential patterning of proteins. Related to Figure 4. (A-DD)** Cryosections from E11.5-E14.5, P3 and adult were stained with antibodies against: **(A-F, A'-D')** EMILIN1 (green); **(G-L, G'-J')** perlecan (HSPG2; red); **(M-R, M'-P')** myosin heavy chain, a marker for differentiated skeletal muscle (MY32; blue); **(S-X, S'-V')** merge (green, red and blue); and **(Y-DD, Y'-BB')** merge with DAPI (grey). **(EE-PP)** Secondary antibody only negative controls: **(EE-JJ)**

merge; and **(KK-PP)** merge with DAPI. Insets (indicated with ') are a 3× enlargement of the forelimb containing the nascent elbow for E11.5-E14.5 at the location indicated with \*. Scale bars=200 μm.